Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03042728 · ClinicalTrials.gov registry record · NA

Impact of Inclusion of a Therapy Dog Visit as Part of the Fibromyalgia Treatment Program

A NA study, sponsored by Mayo Clinic.

Completed
Registry status
NA
Development phase
229
Enrollment target

NCT03042728: Completed NA study, sponsored by Mayo Clinic.

NCT03042728 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 229 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT03042728, a NA study, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
NA
Development phase
229 participants
Enrollment target

Study Summary

In this study the investigators hypothesize that the presence of a Mayo Clinic certified therapy dog will provide additional benefits above typical therapy for patients suffering from fibromyalgia currently enrolled in the Mayo Clinic Fibromyalgia Program.

Primary Outcome

The FIQR questionnaire consists of 21 questions in 3 domains. Each question has 11 boxes similar to a visual analog scale, rating the item from no difficulty to very difficult. To score the FIQR, the researcher must sum the answers for each domain. Then the function domain is divided by 3, the overall impact domain remains unchanged, and the symptom domain score is divided by 2. The resulting scores are added, and final score can range from 0 -100, with 0=no difficulty, and 100=great difficulty.

Interventions

  • BEHAVIORAL Dog Interaction
  • BEHAVIORAL Human Interaction

Trial Details

FieldValue
Enrollment Target 229 participants
Start Date 2017-09-07
Est. Completion 2018-10-20
Phase NA
Mayo Clinic

2,844 total trials

What the finished NCT03042728 record still lists

NCT03042728 is an interventional study that assigns participants to a tested intervention. The registered 229 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower).

The record links to 0 conditions, and to 2 interventions - of which Dog Interaction is the first listed.

NCT03042728 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03042728 about?

NCT03042728 is a clinical study titled "Impact of Inclusion of a Therapy Dog Visit as Part of the Fibromyalgia Treatment Program". In this study the investigators hypothesize that the presence of a Mayo Clinic certified therapy dog will provide additional benefits above typical therapy for patients suffering from fibromyalgia currently enrolled in the Mayo Clinic Fibromyalgia Program.

What is the current status of trial NCT03042728?

This trial is currently completed. It is a NA study. The enrollment target is 229 participants. The study started on 2017-09-07. Estimated completion is 2018-10-20.

What interventions are being tested in trial NCT03042728?

The interventions under investigation include: Dog Interaction (BEHAVIORAL), Human Interaction (BEHAVIORAL).

Who is sponsoring clinical trial NCT03042728?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03042728's enrollment target sits among peer trials

229 468th of 2000 higher than 1,533 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02710253 · 230 participants · Phase 2

    Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy

  • NCT02777879 · 230 participants

    Lung Microbiome and Inflammation in Early COPD

  • NCT03824483 · 230 participants · Phase 2

    Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

  • NCT03833622 · 230 participants · NA

    Shared Decision Making to Improve Goals of Care in the ED

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03042728, the US trial registry maintained by the National Library of Medicine. NCT03042728 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.